- Home
- CVM vs NRXS Comparison
CVM vs NRXS Comparison
Compare CVM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- NRXS
- Stock Information
- Founded
- CVM 1983
- NRXS 2011
- Country
- CVM United States
- NRXS United States
- Employees
- CVM N/A
- NRXS N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- NRXS
- Sector
- CVM Health Care
- NRXS
- Exchange
- CVM Nasdaq
- NRXS Nasdaq
- Market Cap
- CVM 11.8M
- NRXS 13.0M
- IPO Year
- CVM 1987
- NRXS 2023
- Fundamental
- Price
- CVM $3.46
- NRXS $2.43
- Analyst Decision
- CVM
- NRXS Strong Buy
- Analyst Count
- CVM 0
- NRXS 1
- Target Price
- CVM N/A
- NRXS $7.00
- AVG Volume (30 Days)
- CVM 1.6M
- NRXS 107.2K
- Earning Date
- CVM 08-14-2025
- NRXS 08-08-2025
- Dividend Yield
- CVM N/A
- NRXS N/A
- EPS Growth
- CVM N/A
- NRXS N/A
- EPS
- CVM N/A
- NRXS N/A
- Revenue
- CVM N/A
- NRXS $2,934,945.00
- Revenue This Year
- CVM N/A
- NRXS $138,883.78
- Revenue Next Year
- CVM N/A
- NRXS $118.59
- P/E Ratio
- CVM N/A
- NRXS N/A
- Revenue Growth
- CVM N/A
- NRXS 27.52
- 52 Week Low
- CVM $1.98
- NRXS $1.33
- 52 Week High
- CVM $66.60
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- CVM 57.66
- NRXS 47.39
- Support Level
- CVM $2.24
- NRXS $2.23
- Resistance Level
- CVM $2.71
- NRXS $2.75
- Average True Range (ATR)
- CVM 0.51
- NRXS 0.17
- MACD
- CVM 0.25
- NRXS -0.01
- Stochastic Oscillator
- CVM 25.61
- NRXS 38.46
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).